Akoya Biosciences, Inc. (AKYA)
Market Cap | 188.70M |
Revenue (ttm) | 96.63M |
Net Income (ttm) | -63.32M |
Shares Out | 49.14M |
EPS (ttm) | -1.43 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 60,492 |
Open | 3.910 |
Previous Close | 3.910 |
Day's Range | 3.820 - 3.970 |
52-Week Range | 3.040 - 8.800 |
Beta | 1.48 |
Analysts | Buy |
Price Target | 8.75 (+126.39%) |
Earnings Date | May 6, 2024 |
About AKYA
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microar... [Read more]
Financial Performance
In 2023, AKYA's revenue was $96.63 million, an increase of 29.09% compared to the previous year's $74.86 million. Losses were -$63.32 million, -10.36% less than in 2022.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for AKYA stock is "Buy." The 12-month stock price forecast is $8.75, which is an increase of 126.39% from the latest price.
News
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale
MARLBOROUGH, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced it will highlight case studies featuring its Spatial Biolo...
Akoya Biosciences Names BostonGene as a Qualified CRO Service Provider
WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced today that it has been named as a qualified contract research organizat...
Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook
Q4 2023 revenue $26.5 million and FY 2023 revenue $96.6 million Guiding FY 2024 revenue range $114.0-118.0 million and operating cash flow breakeven by YE 2024
Akoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor Conference
MARLBOROUGH, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the fou...
Akoya Biosciences' Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases
PhenoCycler®-Fusion system selected as the Centre's platform technology for advanced spatial biology studies PhenoCycler®-Fusion system selected as the Centre's platform technology for advanced spatia...
Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D.
Leading immunotherapy and immunobiology experts will offer strategic direction and expertise in translational, clinical, and diagnostic applications of Akoya's spatial biology solutions Leading immuno...
Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform
MaxFuse enables matching and integration of datasets from spatial proteomics, spatial transcriptomics, single-cell sequencing, or other modalities
Akoya Biosciences Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2023 and Provides 2024 Outlook
MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quart...
Akoya Biosciences and Thermo Fisher Scientific Announce a License and Distribution Agreement to Deliver Spatial Multiomics Workflow
The Thermo Fisher Scientific ViewRNA technology combined with Akoya's market leading spatial biology solutions will enable rapid, whole-slide imaging of RNA and protein biomarkers The Thermo Fisher Sc...
Akoya to Participate at 42nd Annual J.P. Morgan Healthcare Conference
MARLBOROUGH, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in the 42nd Annual J...
Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
Q3 2023 revenue $25.2 million, 34% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million
Akoya to Participate at Three Upcoming Investor Conferences
MARLBOROUGH, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Company management will be participating in t...
Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023
Spatial Biology 2.0 solutions enable discovery and translational workflows at an unprecedented speed and scale Global network of CROs providing Akoya's spatial phenotyping solutions will also exhibit ...
Akoya Biosciences Announces Peer-Reviewed Publication Using Ultrahigh-Plex Spatial Phenotyping of Head and Neck Cancer to Identify Distinct Immune and Metabolic Signatures
MARLBOROUGH, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that researchers from Akoya Biosciences and The Un...
Akoya to Report Third Quarter 2023 Financial Results on November 8th, 2023
MARLBOROUGH, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the thi...
Akoya Biosciences Sets a New Standard for Scaling Spatial Biology with the Launch of 2.0 Platforms
MARLBOROUGH, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today highlighted the industry-leading scale and speed in whole-s...
Akoya Reports Record Revenue in the Second Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
Q2 2023 revenue $23.5 million, 31% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million
Akoya Biosciences Announces Milestone of 1,000 Peer-Reviewed Publications Citing Use of its Spatial Biology Technologies
MARLBOROUGH, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences , Inc. (Nasqad: AKYA)(“Akoya), The Spatial Biology Company®, today announced a momentous achievement - publication of the 1,000t...
Akoya to Report Second Quarter 2023 Financial Results on August 7th, 2023
MARLBOROUGH, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the sec...
Akoya to Participate at Two Upcoming Investor Conferences
MARLBOROUGH, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Company management will be participating in t...
Akoya Biosciences Announces Pricing of Public Offering of Common Stock
MARLBOROUGH, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the pricing of its public offering of 8,700,000 sh...
Akoya Biosciences shares fall 10% on executive exits, stock offering
Shares of Akoya Biosciences AKYA, -2.46% on Wednesday dropped 10% to $5.00 in after-hours trading after the company said it fired its chief medical officer and chief people officer as part of a cost-c...
Akoya Biosciences Announces Public Offering of Common Stock
MARLBOROUGH, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced it has launched an underwritten public offering of...
Akoya Reports Record Revenue in the First Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
Q1 2023 revenue $21.4 million, 27% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million
Akoya Biosciences Marks Milestone Achievement with Shipment of 1,000th Spatial Biology Instrument
MARLBOROUGH, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced it has shipped it's 1,000th instrument, a signifi...